Clinical Trials

7 (Demo)

When will companies stop babysitting the NANNIs for their clinical trials? 5 key takeaways from SCOPE 2020

SCOPE continues to be a central location for industry colleagues to meet and exchange ideas around clinical development. We had a great time at the 2020 meeting catching up with friends, clients and colleagues, as well as co-moderating a roundtable on protocol design and chairing a main session on site selection with esteemed industry practitioners. It was a whirlwind of…

shutterstock_651441421_1920x960

Less artificial…More INTELLIGENCE

In the industry of clinical research, we are accustomed to working with conservative companies that make decisions slowly.  Look at the adoption of EDC – over how many decades now?  Understandable, at least to a point.   I’ve been in my new role at  Phesi for 2 weeks now, and I am witnessing a refreshing change.  Artificial intelligence started to sneak…

nash-featured-l

Delivering NASH trials in a competitive world using ClinSite

In our last blog we talked about the importance of site level insights in making solid decisions about which investigators can successfully support your trial. In this blog we give further insights about how ClinSite can support decision making on investigator site selection in NASH, a fiercely competitive space for investigator site patient enrollment. When we launched ClinSite at DIA…

ai-is-the-next-step-in-human-evolution.001

A Lot To Be Thankful For

As we head into Thanksgiving, we reflect upon all we have accomplished since January and our vision for 2020. At Phesi, we had quite a few firsts in 2019 and much to be thankful for, such as: Successfully launching our flagship product, ClinSite™ – a self-service, artificial intelligence (AI)-powered tool that enables biopharmaceutical companies to search for and select top-performing…

site-insights-blog-1

Clinical Trial Site-Level Insights

Have you ever felt uncertain that you are selecting the right site for your study? Do you wish you had some objective insights to supplement the capabilities your potential investigator reported on the site selection survey? What if you had insights into competition at the site and investigator level? What if you knew the types of studies, interventions and outcome…

Thoughtful frustrated woman sitting at table near laptop

Filling the Tech Gap in Metastatic Breast Cancer Clinical Trials

According to the American Cancer Society (ACS), a woman living in the United States has a 1 in 8 chance of developing breast cancer, the second-leading cause of cancer death in women (behind only lung cancer). Despite advances in treatment, about 30% of women initially diagnosed with early-stage breast cancer will have a recurrence or experience metastatic disease.[i] Moreover, while…

Advanced Medical Technology

My Journey to AI-driven Clinical Trials

Throughout my two-decade career in the biopharmaceutical industry, my goal has been to make drug development more efficient while reducing costs, and to help the companies I have worked for increase revenue without compromising quality. In pursuing that goal, I have strived to embrace advanced technologies and to optimize organizational and operational structures. Now that I have joined Phesi, I…

b006

Pharma and Biotech are Waiting for 21st Century Clinical Trial Data Analytics Engines

As a repository of clinical trial information, few databases are as trusted – or as widely used – as www.clinicaltrials.gov. A service of the U.S. National Library of Medicine, clinicaltrials.gov aims to provide comprehensive information on privately and publicly funded clinical studies conducted around the world. Many drug developers mine the database to facilitate decisions on trial design, investigator recruitment,…

b007

Predicting Investigator Site Enrollment Performance: Separating Myth from Truth

Throughout my two-decade career in the biopharmaceutical industry, my goal has been to make drug development more efficient while reducing costs, and to help the companies I have worked for increase revenue without compromising quality. In pursuing that goal, I have strived to embrace advanced technologies and to optimize organizational and operational structures. Now that I have joined Phesi, I…

b009

Site, Investigator, or Investigator Site?

The life sciences industry is riddled with casually used terms, acronyms and phrases which are often used out of context or defined differently among companies or individuals. This becomes especially problematic when developing and designing clinical trials, as terms that are tossed around as ‘givens’ can be much more complex processes that may dictate success or failure of a clinical…